237 related articles for article (PubMed ID: 36519216)
1. Prognostic value of Growth differentiation factors 15 in Acute heart failure patients with preserved ejection fraction.
Yin D; Yan X; Bai X; Tian A; Gao Y; Li J
ESC Heart Fail; 2023 Apr; 10(2):1025-1034. PubMed ID: 36519216
[TBL] [Abstract][Full Text] [Related]
2. Growth differentiation factor 15 as mortality predictor in heart failure patients with non-reduced ejection fraction.
Mendez Fernandez AB; Ferrero-Gregori A; Garcia-Osuna A; Mirabet-Perez S; Pirla-Buxo MJ; Cinca-Cuscullola J; Ordonez-Llanos J; Roig Minguell E
ESC Heart Fail; 2020 Oct; 7(5):2223-2229. PubMed ID: 32589369
[TBL] [Abstract][Full Text] [Related]
3. Biomarkers for characterization of heart failure - Distinction of heart failure with preserved and reduced ejection fraction.
Sinning C; Kempf T; Schwarzl M; Lanfermann S; Ojeda F; Schnabel RB; Zengin E; Wild PS; Lackner KJ; Munzel T; Blankenberg S; Wollert KC; Zeller T; Westermann D
Int J Cardiol; 2017 Jan; 227():272-277. PubMed ID: 27838133
[TBL] [Abstract][Full Text] [Related]
4. Growth differentiation factor 15 in heart failure with preserved vs. reduced ejection fraction.
Chan MM; Santhanakrishnan R; Chong JP; Chen Z; Tai BC; Liew OW; Ng TP; Ling LH; Sim D; Leong KT; Yeo PS; Ong HY; Jaufeerally F; Wong RC; Chai P; Low AF; Richards AM; Lam CS
Eur J Heart Fail; 2016 Jan; 18(1):81-8. PubMed ID: 26497848
[TBL] [Abstract][Full Text] [Related]
5. [Prognostic value of N-terminal B-type natriuretic peptide on all-cause mortality in heart failure patients with preserved ejection fraction].
Cao J; Jin XJ; Zhou J; Chen ZY; Xu DL; Yang XC; Dong W; Li LW; Luo J; Chen L; Fu M; Zhou JM; Ge JB
Zhonghua Xin Xue Guan Bing Za Zhi; 2019 Nov; 47(11):875-881. PubMed ID: 31744276
[No Abstract] [Full Text] [Related]
6. Biomarker-driven prognostic models in chronic heart failure with preserved ejection fraction: the EMPEROR-Preserved trial.
Pocock SJ; Ferreira JP; Packer M; Zannad F; Filippatos G; Kondo T; McMurray JJV; Solomon SD; Januzzi JL; Iwata T; Salsali A; Butler J; Anker SD
Eur J Heart Fail; 2022 Oct; 24(10):1869-1878. PubMed ID: 35796209
[TBL] [Abstract][Full Text] [Related]
7. Utility of Growth Differentiation Factor-15, A Marker of Oxidative Stress and Inflammation, in Chronic Heart Failure: Insights From the HF-ACTION Study.
Sharma A; Stevens SR; Lucas J; Fiuzat M; Adams KF; Whellan DJ; Donahue MP; Kitzman DW; Piña IL; Zannad F; Kraus WE; O'Connor CM; Felker GM
JACC Heart Fail; 2017 Oct; 5(10):724-734. PubMed ID: 28958347
[TBL] [Abstract][Full Text] [Related]
8. Growth differentiation factor-15 as a prognostic marker in patients with acute myocardial infarction.
Khan SQ; Ng K; Dhillon O; Kelly D; Quinn P; Squire IB; Davies JE; Ng LL
Eur Heart J; 2009 May; 30(9):1057-65. PubMed ID: 19168526
[TBL] [Abstract][Full Text] [Related]
9. Prognostic value of growth differentiation factor-15 in Chinese patients with heart failure: A prospective observational study.
Wang H; Chen Q; Li Y; Jing X; Yang J
Cardiol J; 2018; 25(2):245-253. PubMed ID: 28612904
[TBL] [Abstract][Full Text] [Related]
10. Multimarker Analysis of Serially Measured GDF-15, NT-proBNP, ST2, GAL-3, cTnI, Creatinine, and Prognosis in Acute Heart Failure.
Gürgöze MT; van Vark LC; Baart SJ; Kardys I; Akkerhuis KM; Manintveld OC; Postmus D; Hillege HL; Lesman-Leegte I; Asselbergs FW; Brunner-la-Rocca HP; van den Bos EJ; Orsel JG; de Ridder SPJ; Pinto YM; Boersma E
Circ Heart Fail; 2023 Jan; 16(1):e009526. PubMed ID: 36408685
[TBL] [Abstract][Full Text] [Related]
11. Growth differentiation factor-15 combined with N-terminal prohormone of brain natriuretic peptide increase 1-year prognosis prediction value for patients with acute heart failure: a prospective cohort study.
Hao J; Cheang I; Zhang L; Wang K; Wang HM; Wu QY; Zhou YL; Zhou F; Xu DJ; Zhang HF; Yao WM; Li XL
Chin Med J (Engl); 2019 Oct; 132(19):2278-2285. PubMed ID: 31567379
[TBL] [Abstract][Full Text] [Related]
12. Growth differentiation factor 15, ST2, high-sensitivity troponin T, and N-terminal pro brain natriuretic peptide in heart failure with preserved vs. reduced ejection fraction.
Santhanakrishnan R; Chong JP; Ng TP; Ling LH; Sim D; Leong KT; Yeo PS; Ong HY; Jaufeerally F; Wong R; Chai P; Low AF; Richards AM; Lam CS
Eur J Heart Fail; 2012 Dec; 14(12):1338-47. PubMed ID: 22869458
[TBL] [Abstract][Full Text] [Related]
13. Additional Diagnostic Value of Growth Differentiation Factor-15 (GDF-15) to N-Terminal B-Type Natriuretic Peptide (NT-proBNP) in Patients with Different Stages of Heart Failure.
Li J; Cui Y; Huang A; Li Q; Jia W; Liu K; Qi X
Med Sci Monit; 2018 Jul; 24():4992-4999. PubMed ID: 30019695
[TBL] [Abstract][Full Text] [Related]
14. Prognostic Value of Multiple Circulating Biomarkers for 2-Year Death in Acute Heart Failure With Preserved Ejection Fraction.
Gao Y; Bai X; Lu J; Zhang L; Yan X; Huang X; Dai H; Wang Y; Hou L; Wang S; Tian A; Li J
Front Cardiovasc Med; 2021; 8():779282. PubMed ID: 34957261
[No Abstract] [Full Text] [Related]
15. Reductions in N-Terminal Pro-Brain Natriuretic Peptide Levels Are Associated With Lower Mortality and Heart Failure Hospitalization Rates in Patients With Heart Failure With Mid-Range and Preserved Ejection Fraction.
Savarese G; Hage C; Orsini N; Dahlström U; Perrone-Filardi P; Rosano GM; Lund LH
Circ Heart Fail; 2016 Nov; 9(11):. PubMed ID: 28029640
[TBL] [Abstract][Full Text] [Related]
16. Combination of high-sensitivity troponin I and N-terminal pro-B-type natriuretic peptide predicts future hospital admission for heart failure in high-risk hypertensive patients with preserved left ventricular ejection fraction.
Okuyama R; Ishii J; Takahashi H; Kawai H; Muramatsu T; Harada M; Yamada A; Motoyama S; Matsui S; Naruse H; Sarai M; Hasegawa M; Watanabe E; Suzuki A; Hayashi M; Izawa H; Yuzawa Y; Ozaki Y
Heart Vessels; 2017 Jul; 32(7):880-892. PubMed ID: 28154958
[TBL] [Abstract][Full Text] [Related]
17. The utility of growth differentiation factor-15, galectin-3, and sST2 as biomarkers for the diagnosis of heart failure with preserved ejection fraction and compared to heart failure with reduced ejection fraction: a systematic review.
Rabkin SW; Tang JKK
Heart Fail Rev; 2021 Jul; 26(4):799-812. PubMed ID: 32472523
[TBL] [Abstract][Full Text] [Related]
18. Prognostic value of NT-proBNP in heart failure with preserved versus reduced EF.
Kang SH; Park JJ; Choi DJ; Yoon CH; Oh IY; Kang SM; Yoo BS; Jeon ES; Kim JJ; Cho MC; Chae SC; Ryu KH; Oh BH;
Heart; 2015 Dec; 101(23):1881-8. PubMed ID: 26319121
[TBL] [Abstract][Full Text] [Related]
19. Incremental prognostic power of novel biomarkers (growth-differentiation factor-15, high-sensitivity C-reactive protein, galectin-3, and high-sensitivity troponin-T) in patients with advanced chronic heart failure.
Lok DJ; Klip IT; Lok SI; Bruggink-André de la Porte PW; Badings E; van Wijngaarden J; Voors AA; de Boer RA; van Veldhuisen DJ; van der Meer P
Am J Cardiol; 2013 Sep; 112(6):831-7. PubMed ID: 23820571
[TBL] [Abstract][Full Text] [Related]
20. Limited value of NT-proBNP as a prognostic marker of all-cause mortality in patients with heart failure with preserved and mid-range ejection fraction in primary care: A report from the swedish heart failure register.
Eriksson B; Wändell P; Dahlström U; Näsman P; Lund LH; Edner M
Scand J Prim Health Care; 2019 Dec; 37(4):434-443. PubMed ID: 31724475
[No Abstract] [Full Text] [Related]
[Next] [New Search]
